Drugs

, Volume 73, Issue 11, pp 1227–1244 | Cite as

Shingles (Herpes Zoster) Vaccine (Zostavax®): A Review of Its Use in the Prevention of Herpes Zoster and Postherpetic Neuralgia in Adults Aged ≥50 Years

Adis Drug Evaluation

Abstract

The live, attenuated shingles (herpes zoster) vaccine Zostavax® is approved in the EU for use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years. In adults aged ≥60 years, zoster vaccine reduced the burden of illness associated with herpes zoster, with reductions in the incidence of postherpetic neuralgia and herpes zoster, according to the results of the Shingles Prevention Study. Results of subsequent Short- and Long-Term Persistence Substudies indicate that the efficacy of zoster vaccine is maintained in the longer term, albeit with a gradual decline over time. In the Zostavax Efficacy and Safety Trial, zoster vaccine reduced the incidence of herpes zoster in adults aged 50–59 years. Findings of these studies are supported by the results of large, retrospective, cohort studies. Zoster vaccine was generally well tolerated, with injection-site adverse events being the most commonly reported adverse events. In conclusion, zoster vaccine provides an important opportunity to reduce the burden of illness associated with herpes zoster by reducing the incidence of herpes zoster and postherpetic neuralgia.

References

  1. 1.
    Drolet M, Oxman MN, Levin MJ, et al. Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother. 2013;9(5).Google Scholar
  2. 2.
    Fashner J, Bell AL. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Phys. 2011;83(12):1432–7.Google Scholar
  3. 3.
    Li H-T, Lu S, Liu J-M. Herpes zoster vaccination in people aged 50–59 years. Clin Infect Dis. 2012;54(7):929–30.CrossRefPubMedGoogle Scholar
  4. 4.
    Pinchinat S, Cebrián-Cuenca AM, Bricout H, et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13(1):170.CrossRefPubMedGoogle Scholar
  5. 5.
    Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs. 2008;22(5):417–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Johnson RW, Wasner G, Saddier P, et al. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging. 2008;25(12):991–1006.CrossRefPubMedGoogle Scholar
  8. 8.
    European Medicines Agency. Zostavax (shingles [herpes zoster] vaccine (live]): EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000674/WC500053462.pdf. Accessed 11 Jun 2013.
  9. 9.
    Sanofi Pasteur MSD Limited. Varivax (varicella vaccine [live]): UK summary of product characteristics. 2013. http://www.medicines.org.uk/emc/medicine/15264/SPC/VARIVAX/. Accessed 11 Jun 2013.
  10. 10.
    Gilderman LI, Lawless JF, Nolen TM, et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol. 2008;15(2):314–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Sanford M, Keating GM. Zoster vaccine (Zostavax®): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010;27(2):159–76.CrossRefPubMedGoogle Scholar
  12. 12.
    Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis. 2012;54(7):922–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197(6):825–35.CrossRefPubMedGoogle Scholar
  14. 14.
    Levin MJ, Schmader KE, Zerbe GO, et al. Safety, tolerability, and immunogenicity of a booster dose of zoster vaccine (ZV) administered ≥10 years after a first dose compared with a first dose of ZV [abstract]. 20th IAGG World Congress of Gerontology and Geriatrics; 23–27 Jun 2013; Seoul.Google Scholar
  15. 15.
    Merck. Safety, tolerability, and immunogenicity of a booster dose of zoster vaccine, live (V211-029 AM1) [ClinicalTrials.gov identifier NCT01245751] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01245751. Accessed 12 Jun 2013.
  16. 16.
    Parrino J, Marquez F, Fisher CL, et al. Safety, tolerability, and immunogenicity of zoster vaccine in patients on chronic/maintenance corticosteroids [abstract]. Arthritis Rheum. 2011;63(Suppl 10):2071.Google Scholar
  17. 17.
    Wasan S, Berg A, Liang YM, et al. Immune response and safety of herpes zoster vaccine in IBD patients on methotrexate or thiopurines [abstract no. 1651]. Am J Gastroenterol. 2012;107(Suppl 1):S668.Google Scholar
  18. 18.
    Benson C, Hua L, Andersen J, et al. Zostavax is generally safe and immunogenic in HIV + adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebo- controlled trial [abstract no. 96]. 19th Conference on Retroviruses and Opportunistic Infections; 5–8 Mar 2012; Seattle (WA).Google Scholar
  19. 19.
    National Institute of Allergy and Infectious Diseases. Live zoster vaccine in HIV-infected adults on antiretroviral therapy [ClinicalTrials.gov identifier NCT00851786] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT00851786. Accessed 11 Jun 2013.
  20. 20.
    Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009;200(7):1068–77.CrossRefPubMedGoogle Scholar
  21. 21.
    Irwin MR, Levin MJ, Laudenslager ML, et al. Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis. 2013;56(8):1085–93.CrossRefPubMedGoogle Scholar
  22. 22.
    Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine. 2010;28(25):4204–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Arnou R, Fiquet A, Thomas S, et al. Immunogenicity and safety of Zostavax® approaching expiry potency in individuals aged ≥50 years. Hum Vaccin. 2011;7(10):1060–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of Zostavax and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc. 2007;55(10):1499–507.CrossRefPubMedGoogle Scholar
  25. 25.
    Vermeulen JN, Lange JMA, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine. 2012;30(5):904–10.CrossRefPubMedGoogle Scholar
  26. 26.
    MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old. Hum Vaccin. 2010;6(11):894–902.CrossRefPubMedGoogle Scholar
  27. 27.
    Vesikari T, Hardt R, Rümke HC, et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥70 years: a randomized study of a single dose versus two different two-dose schedules. Hum Vaccin Immunother. 2013;9:4.CrossRefGoogle Scholar
  28. 28.
    Sutradhar SC, Wang WWB, Schlienger K, et al. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older. Clin Vaccine Immunol. 2009;16(5):646–52.CrossRefPubMedGoogle Scholar
  29. 29.
    Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.CrossRefPubMedGoogle Scholar
  30. 30.
    Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clin Infect Dis. 2012;55(10):1320–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10(4):e1001420.CrossRefPubMedGoogle Scholar
  32. 32.
    Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305(2):160–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Tseng HF, Chi M, Smith N, et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis. 2012;206(2):190–6.CrossRefPubMedGoogle Scholar
  34. 34.
    Tseng HF, Smith N, Sy LS, et al. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine. 2011;29(20):3628–32.CrossRefPubMedGoogle Scholar
  35. 35.
    Zhang J, Delzell E, Xie F, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther. 2011;13(5):R174.CrossRefPubMedGoogle Scholar
  36. 36.
    Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Schmader KE, Johnson GR, Saddier P, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010;58(9):1634–41.CrossRefPubMedGoogle Scholar
  38. 38.
    Merck and Co. Inc. Zostavax® (zoster vaccine live) [refrigerator stable] suspension for subcutaneous injection: US prescribing information. 2011. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM285015.pdf. Accessed 28 May 2013.
  39. 39.
    Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the Shingles Prevention Study: a randomized trial. Ann Intern Med. 2010;152(9):545–54.CrossRefPubMedGoogle Scholar
  40. 40.
    Morrison VA, Oxman MN, Levin MJ, et al. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013;. doi:10.1093/infdis/jit182.Google Scholar
  41. 41.
    Murray AV, Reisinger KS, Kerzner B, et al. Safety and tolerability of zoster vaccine in adults ≥60 years old. Hum Vaccin. 2011;7(11):1130–6.CrossRefPubMedGoogle Scholar
  42. 42.
    Tseng HF, Liu A, Sy L, et al. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med. 2012;271(5):510–20.CrossRefPubMedGoogle Scholar
  43. 43.
    Baxter R, Tran TN, Hansen J, et al. Safety of Zostavax™: a cohort study in a managed care organization. Vaccine. 2012;30(47):6636–41.CrossRefPubMedGoogle Scholar
  44. 44.
    Annemans L, Bresse X, Gobbo C, et al. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ. 2010;13(3):537–51.CrossRefPubMedGoogle Scholar
  45. 45.
    Bilcke J, Marais C, Ogunjimi B, et al. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine. 2012;30(3):675–84.CrossRefPubMedGoogle Scholar
  46. 46.
    van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454–67.CrossRefPubMedGoogle Scholar
  47. 47.
    Moore L, Remy V, Martin M, et al. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Effect Resour Allocat. 2010;8(7).Google Scholar
  48. 48.
    van Lier A, van Hoek AJ, Opstelten W, et al. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010;10:237.CrossRefPubMedGoogle Scholar
  49. 49.
    de Boer PT, Pouwels KB, Cox JM, et al. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine. 2013;31(9):1276–83.CrossRefPubMedGoogle Scholar
  50. 50.
    Szucs TD, Kressig RW, Papageorgiou M, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2011;7(7):749–56.CrossRefPubMedGoogle Scholar
  51. 51.
    Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494–500.CrossRefPubMedGoogle Scholar
  52. 52.
    Oxman MN, Gershon AA, Poland GA. Zoster vaccine recommendations: the importance of using a clinically valid correlate of protection. Vaccine. 2011;29(20):3625–7.CrossRefPubMedGoogle Scholar
  53. 53.
    Drolet M, Brisson M, Levin MJ, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain. 2010;26(8):656–66.PubMedGoogle Scholar
  54. 54.
    White RR, Lenhart G, Singhal PK, et al. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics. 2009;27(9):781–92.CrossRefPubMedGoogle Scholar
  55. 55.
    Merck. Zostavax™ (zoster vaccine live) long-term effectiveness study (V211-024) [ClinicalTrials.gov identifier NCT01600079] US National Institutes of Health, ClinicalTrials.gov. 2012. http://www.clinicaltrials.gov/ct2/show/NCT01600079. Accessed 11 Jun 2013.
  56. 56.
    Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37.CrossRefPubMedGoogle Scholar
  57. 57.
    Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Can Med Assoc J. 2010;182(16):1731–6.CrossRefGoogle Scholar
  58. 58.
    Harpaz R, Nagel MA, Schmader K, et al. Roundtable on postherpetic neuralgia: what, why, how long, and what’s next? Popul Health Manag. 2012;15(6):385–90.CrossRefPubMedGoogle Scholar
  59. 59.
    Ultsch B, Siedler A, Rieck T, et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.CrossRefPubMedGoogle Scholar
  60. 60.
    Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137(1):38–47.CrossRefPubMedGoogle Scholar
  61. 61.
    Bilcke J, Ogunjimi B, Hulstaert F, et al. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine. 2012;30(17):2795–800.CrossRefPubMedGoogle Scholar
  62. 62.
    Gilden D. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. J Intern Med. 2011;269(5):496–506.CrossRefPubMedGoogle Scholar
  63. 63.
    Lu P-J, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med. 2011;40(2):e1–6.CrossRefPubMedGoogle Scholar
  64. 64.
    Elkin Z, Cohen EJ, Goldberg JD, et al. Studying physician knowledge, attitudes, and practices regarding the herpes zoster vaccine to address perceived barriers to vaccination. Cornea. 2013;32(7):976–81.CrossRefPubMedGoogle Scholar
  65. 65.
    Javed S, Javed F, Mays RM, et al. Herpes zoster vaccine awareness among people = 50 years of age and its implications on immunization. Dermatol Online J. 2012;18(8):2.PubMedGoogle Scholar
  66. 66.
    Hurley LP, Lindley MC, Harpaz R, et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med. 2010;152(9):555–60.CrossRefPubMedGoogle Scholar
  67. 67.
    Gerberding J, Yawn BP. Discussing the zoster vaccine: an interview with Julie Gerberding, president of Merck vaccines. Popul Health Manag. 2012;15(6):382–4.CrossRefPubMedGoogle Scholar
  68. 68.
    European Medicines Agency. Zostavax (zoster vaccine): scientific discussion—variation. 2007. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000674/human_med_001185.jsp&mid=WC0b01ac058001d124. Accessed 29 May 2013.
  69. 69.
    Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2013. Ann Intern Med. 2013;158(3):191–9.CrossRefGoogle Scholar
  70. 70.
    National Health Service. The NHS vaccination schedule. 2013. http://www.nhs.uk/Conditions/vaccinations/Pages/vaccination-schedule-age-checklist.aspx. Accessed 11 Jun 2013.
  71. 71.
    Sanofi Pasteur MSD. UK first major European country to run Zostavax nationwide shingles vaccination programme [media release]. 2013. http://www.spmsd.com/news/uk-first-major-european-country-to-run-zostavax-nationwide-shingles-vaccination-programme/. Accessed 11 Jun 2013.

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations